File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 2018 APLAR axial spondyloarthritis treatment recommendations

Title2018 APLAR axial spondyloarthritis treatment recommendations
Authors
Keywordsankylosing spondylitis
axial spondyloarthritis
treatment
Issue Date2019
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd
Citation
International Journal of Rheumatic Diseases, 2019, v. 22 n. 3, p. 340-356 How to Cite?
AbstractIntroduction: Despite the availability of axial spondyloarthritis (SpA) recommendations proposed by various rheumatology societies, we considered that a region‐specific guideline was of substantial added value to clinicians of the Asia‐Pacific region, given the wide variations in predisposition to infections and other patient factors, local practice patterns, and access to treatment across countries. Materials and methods: Systematic reviews were undertaken of English‐language articles published between 2000 and 2016, identified from MEDLINE using PubMed, EMBASE and Cochrane databases. The strength of available evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Recommendations were developed through consensus using the Delphi technique. Results: Fourteen axial SpA treatment recommendations were developed based on evidence summaries and consensus. The first 2 recommendations cover non‐pharmacological approaches to management. Recommendations 3 to 5 describe the following: the use of non‐steroidal anti‐inflammatory drugs as first‐line symptomatic treatment; the avoidance of long‐term corticosteroid use; and the utility of conventional synthetic disease‐modifying anti‐rheumatic drugs (csDMARDs) for peripheral or extra‐articular manifestations. Recommendation 6 refers to the indications for biological DMARDs (bDMARDs). Recommendation 7 deals specifically with screening for infections endemic to Asia, prior to use of bDMARDs. Recommendations 7 to 13 cover the role of bDMARDs in the treatment of active axial SpA and include related issues such as continuing therapy and use in special populations. Recommendation 14 deals with the utility of surgical intervention in axial SpA. Conclusion: These recommendations provide up‐to‐date guidance for treatment of axial SpA to help meet the needs of patients and clinicians in the Asia‐Pacific region.
DescriptionLink to Free access
Persistent Identifierhttp://hdl.handle.net/10722/273940
ISSN
2019 Impact Factor: 1.98
2015 SCImago Journal Rankings: 0.536
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTam, LS-
dc.contributor.authorWei, JCC-
dc.contributor.authorAggarwal, A-
dc.contributor.authorBaek, HJ-
dc.contributor.authorCheung, PP-
dc.contributor.authorChiowchanwisawakit, P-
dc.contributor.authorDans, L-
dc.contributor.authorGu, J-
dc.contributor.authorHagino, N-
dc.contributor.authorKishimoto, M-
dc.contributor.authorReyes, HM-
dc.contributor.authorSoroosh, S-
dc.contributor.authorStebbings, S-
dc.contributor.authorWhittle, S-
dc.contributor.authorYeap, SS-
dc.contributor.authorLau, CS-
dc.date.accessioned2019-08-18T14:51:47Z-
dc.date.available2019-08-18T14:51:47Z-
dc.date.issued2019-
dc.identifier.citationInternational Journal of Rheumatic Diseases, 2019, v. 22 n. 3, p. 340-356-
dc.identifier.issn1756-1841-
dc.identifier.urihttp://hdl.handle.net/10722/273940-
dc.descriptionLink to Free access-
dc.description.abstractIntroduction: Despite the availability of axial spondyloarthritis (SpA) recommendations proposed by various rheumatology societies, we considered that a region‐specific guideline was of substantial added value to clinicians of the Asia‐Pacific region, given the wide variations in predisposition to infections and other patient factors, local practice patterns, and access to treatment across countries. Materials and methods: Systematic reviews were undertaken of English‐language articles published between 2000 and 2016, identified from MEDLINE using PubMed, EMBASE and Cochrane databases. The strength of available evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Recommendations were developed through consensus using the Delphi technique. Results: Fourteen axial SpA treatment recommendations were developed based on evidence summaries and consensus. The first 2 recommendations cover non‐pharmacological approaches to management. Recommendations 3 to 5 describe the following: the use of non‐steroidal anti‐inflammatory drugs as first‐line symptomatic treatment; the avoidance of long‐term corticosteroid use; and the utility of conventional synthetic disease‐modifying anti‐rheumatic drugs (csDMARDs) for peripheral or extra‐articular manifestations. Recommendation 6 refers to the indications for biological DMARDs (bDMARDs). Recommendation 7 deals specifically with screening for infections endemic to Asia, prior to use of bDMARDs. Recommendations 7 to 13 cover the role of bDMARDs in the treatment of active axial SpA and include related issues such as continuing therapy and use in special populations. Recommendation 14 deals with the utility of surgical intervention in axial SpA. Conclusion: These recommendations provide up‐to‐date guidance for treatment of axial SpA to help meet the needs of patients and clinicians in the Asia‐Pacific region.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwell-synergy.com/loi/ijrd-
dc.relation.ispartofInternational Journal of Rheumatic Diseases-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectankylosing spondylitis-
dc.subjectaxial spondyloarthritis-
dc.subjecttreatment-
dc.title2018 APLAR axial spondyloarthritis treatment recommendations-
dc.typeArticle-
dc.identifier.emailLau, CS: cslau@hku.hk-
dc.identifier.authorityLau, CS=rp01348-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/1756-185X.13510-
dc.identifier.pmid30816645-
dc.identifier.scopuseid_2-s2.0-85062332373-
dc.identifier.hkuros301859-
dc.identifier.volume22-
dc.identifier.issue3-
dc.identifier.spage340-
dc.identifier.epage356-
dc.identifier.isiWOS:000461908400002-
dc.publisher.placeAustralia-
dc.identifier.issnl1756-1841-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats